Ani Pharmaceuticals (ANIP) Research & Development (2010 - 2026)

Ani Pharmaceuticals (ANIP) has 17 years of Research & Development data on file, last reported at $10.6 million in Q1 2026.

• For the quarter ending Q1 2026, Research & Development changed 0.34% year-over-year to $10.6 million; the trailing twelve-month figure through Mar 2026 stood at $51.7 million (up 15.83% YoY), and the FY2025 full-year result was $51.7 million, up 15.89% from the prior year.
• Research & Development fell to $10.6 million in Q1 2026, from $12.3 million in the prior quarter.
• In the past five years, Research & Development ranged from a high of $16.6 million in Q4 2024 to a low of $4.2 million in Q2 2022.
• A 5-year average of $9.6 million and a median of $10.1 million in 2024 frame the typical range for Research & Development.
• Across the five-year window, Research & Development soared 211.77% in 2022 and retreated 26.34% in 2025, its largest moves.
• Tracing ANIP's Research & Development over 5 years: stood at $5.2 million in 2022, then jumped by 88.95% to $9.9 million in 2023, then soared by 68.7% to $16.6 million in 2024, then fell by 26.34% to $12.3 million in 2025, then slipped by 13.55% to $10.6 million in 2026.
• Business Quant data shows ANIP's Research & Development at $10.6 million in Q1 2026, $12.3 million in Q4 2025, and $12.3 million in Q3 2025.